BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7819101)

  • 1. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
    Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
    Fabre-Guillevin E; Tabrizi R; Coulon V; Monnereau A; Eghbali H; Soubeyran I; Soubeyran P
    Leuk Lymphoma; 2006 Apr; 47(4):603-11. PubMed ID: 16690518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
    Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
    Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
    Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
    Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
    Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
    Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble interleukin-2 receptor levels in patients with non-Hodgkin's lymphoma or with acute leukemia.
    Chang CS; Lin SF; Liu HW
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 May; 21(2):79-84. PubMed ID: 3264231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
    Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
    Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
    Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
    Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
    Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
    Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.